BMO Capital analyst Etzer Darout downgraded ImmunoGen (IMGN) to Market Perform from Outperform with a price target of $31, up from $26, after the company agreed to be acquired by AbbVie (ABBV) for $31.26 per share in cash. The firm sees low ImmunoGen pipeline risks in terms of the deal closing given that the pre-deal price implied little pipeline credit and it expects Elahere to continue to meet or exceed sales expectations in the near term.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMGN: